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Abstract 
Objectives 
To assess healthcare resource use and costs of treating people with clinically 
significant diabetic macular oedema (DMO) with fluocinolone acetonide (FAc) 190 µg 
intravitreal implant in routine clinical practice.  
Methods 
The retrospective Iluvien Clinical Evidence (ICE-UK) study collected data on people 
prescribed the FAc implant in any one of 13 ophthalmology centres between 1 April 
2013 and 15 April 2015. Data were collected for 12 months before and after 
implantation. Standard UK costs were attributed to healthcare resource use. 
Results 
208 people contributing 233 FAc treated eyes were selected. Mean age was 68.1 
years and 62% were male. The mean (standard deviation, SD) number of anti-
vascular endothelial growth factor (anti-VEGF) injections per FAc treated eye in the 
12 months prior to implant was 2.8 (2.5), decreasing to 0.6 (1.4) for the same period 
after implant (p<0.001). The corresponding figures for other steroid injections 
(dexamethasone and triamcinolone) were 0.14 (0.4) before and 0.08 (0.4) after 
implant (p=0.016). There was no statistically significant difference in the number of 
laser therapies required in the 12 months before and after FAc implant (mean 0.12 
versus 0.11, respectively; p=0.626). Overall, mean (SD) healthcare costs were £2,691 
(£1,850) before and £1,239 (£1,203) after FAc implant (p<0.001). The unit drug and 
administration cost per FAc implant was £5,680. 
Conclusions 
Excluding the cost of the FAc implant, healthcare costs were significantly reduced in 
the 12 months post implant. FAc implant has a duration of three years. This needs to 
be considered when interpreting the cost associated with the FAc implant.  
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Introduction 
The prevalence of type 2 diabetes is increasing worldwide due to increasing obesity 
allied to sedentary lifestyle and a general ageing of populations.1 Diabetic 
retinopathy, including diabetic macular oedema (DMO), is the most frequent cause 
of visual loss and blindness in the working-aged segment of the populations of the 
developed nations.2 Increases in this primary cause of visual deterioration will, in 
turn, lead to a substantial rise in the burden of DMO to people with diabetes and 
healthcare providers alike.3 It has been estimated that the healthcare cost of 
managing people with DMO in England, UK, alone was £92 million in 2010.4 
However, since the introduction of anti-VEGF and intravitreal steroid injections, this 
is likely to have increased. Management of DMO varies according to the degree of 
macular thickening,5 with treatment options including laser photocoagulation, anti-
VEGF (vascular endothelial growth factor) therapies and intravitreal steroids.  
Fluocinolone acetonide (FAc) 190 µg intravitreal implant is a licensed intravitreal 
steroid injection approved in the UK for the treatment of visual impairment 
associated with chronic DMO in eyes that have been insufficiently responsive to 
available therapies. A single FAc 190 µg intravitreal implant provides a sustained 
release of FAc for up to three years and has been shown to be effective over this 
period.6 Therefore, compared with intravitreal anti-VEGF therapies, where the doses 
can be administered as frequently as every four weeks, the FAc implant may have a 
significant impact on resource utilisation in busy hospital eye units. Side effects of 
FAc included steroid induced cataracts and raised intraocular pressure (IOP).  
Like all other healthcare interventions, treatments for DMO need to demonstrate 
cost-effectiveness. The UK National Institute for Health and Care Excellence (NICE) 
has confirmed the cost-effectiveness of the FAc implant in eyes with a pseudophakic 
lens based on data from FAME.7 A US economic evaluation using the same data from 
FAME arrived at an incremental cost-effectiveness ratio (ICER) of $38,763 per quality 
adjusted life year (QALY) gained, based on the assumption that 40% of people would 
be treated unilaterally.8 When it was assumed that 100% of people were treated 
unilaterally, the FAc implant was found to be cost saving (ICER -$10,620 per QALY).8  
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The objective of this study was to evaluate healthcare resource use and associated 
financial costs involved in treating DMO in routine clinical practice both before and 
after FAc intravitreal implant, using data from the Iluvien Clinical Evidence study in 
the United Kingdom (ICE-UK). The ICE-UK study was conducted in order to assess the 
effectiveness of FAc intravitreal implant in clinical practice, where people are likely 
to have been exposed to first line anti-VEGF prior to initiation of steroid therapy, a 
reflection of current clinical practice. Since the NICE recommendations, which were 
based on the combined FAME studies, the treatment paradigm for DMO has 
changed, necessitating further research to be conducted in people prescribed anti-
VEGF as first line therapy. Importantly, the ICE-UK study collected data not only after 
implant but also in the 12 months prior to implant, bearing in mind that DMO 
typically involves a gradual deterioration in vision. The availability of such data, 
which are rarely reported, enabled the estimation of healthcare resource use in the 
12 month periods before and after FAc implant.  
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Methods 
Data source 
For this retrospective cohort study, data collected for the ICE-UK study were utilised. 
In brief, data from patient medical records from 13 participating UK ophthalmology 
departments were extracted, pseudonymised and combined into a single dataset. 
Collected data included patient demographics, medical history, implant data, and 
data from multi-disciplinary and medication reviews in the 12 months before and 
after implant. Quantitative data were also generated from medical records and 
administrative records, together with clinical measurements.  
 
Ethical approval 
The lead clinician and Caldicott Guardian at each centre gave written approval for 
extraction of anonymised data. The study protocol was approved by the head of 
research governance at the lead clinical centre. This study was conducted in 
accordance with the Declaration of Helsinki and the UK Data Protection Act. 
 
Subjects 
People with type 1 and type 2 diabetes suffering from DMO were treated with FAc 
intravitreal implant in at least one eye as part of their routine care. In order to 
ensure that subjects were eligible for a minimum follow-up of 12 months post FAc 
implant, only those implants inserted between 1 April 2013 and 15 April 2015 were 
included in the study. Other reasons for insufficient follow-up included: non-
attendance at the clinic, last appointment missed post index, patient had left the 
clinic. Those with insufficient follow-up or with a history of participating in any 
interventional study for DMO were excluded. Only those people with a 12 months’ 
history prior to implant were eligible for inclusion.   
Study eyes were defined as eyes treated with FAc implant and comprised first eyes 
treated with FAc implant (all included people) and, where applicable, second eyes 
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treated with FAc implant, with the index date defined as the date of first recorded 
FAc intravitreal implant into the study eye. Fellow eyes were defined as eyes that 
were not treated with FAc implant. Data were collected for the study eyes from 12 
months prior to and at least 12 months post index date. 
 
Outcomes 
Healthcare resource use and the corresponding financial costs were estimated for 
each study eye for the 12 month period both prior to and post index date. 
Healthcare resources used on the day of FAc implant were regarded as occurring 
post implant. Unit costs applied to healthcare resources are listed in Table 1. The 
cost of outpatient attendances and procedures and inpatient or day case admissions 
were derived using the costs detailed in the NHS National Tariff for England, UK.9 
Reviews recorded in the dataset were assumed to have been incurred during an 
outpatient attendance. Outpatient procedures recorded in the dataset comprised: 
administration of treatments for DMO (anti-VEGF, steroids and macular laser 
therapy) and ocular coherence tomography (OCT).  
Drug costs for treatments for DMO were taken from the current price listed in the 
NHS Dictionary of Medicines and Devices (dm+d) database.10 Costs for bevacizumab 
were not listed in the dm+d database because no licensed formulation of 
bevacizumab is available in the UK for treatment of DMO. Instead unit costs for this 
drug were obtained from the Royal Liverpool and Broadgreen University Hospital, 
manufacturers and suppliers of an unlicensed formulation of bevacizumab. 
The costs of inpatient or day case admissions for cataract operations, glaucoma 
surgery or vitrectomies were taken from the NHS National Tariff for England, UK.9 
Where more than one procedure was carried out on the same date, the NHS HRG4 
(Healthcare Resource Group 4) 2014/15 payment grouper11 was used to determine 
the most appropriate HRG. Procedures and reviews listed on the same date as an 
inpatient admission were assumed to have been carried out as part of the inpatient 
admission. Similarly, where an inpatient or day case procedure was listed for the 
fellow eye, procedures carried out in the study eye were assumed to have taken 
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place as part of the inpatient or day case admission. Procedures carried out in first 
eyes treated with the FAc implant were taken into account when determining the 
cost of procedures carried out in the second treated eye. For example, if a DMO 
treatment was administered to both the first FAc treated eye and second FAc 
treated eye on the same date, the cost applied to the first eye included both the cost 
of administering the drug as part of an outpatient attendance and the drug cost, 
whereas the cost applied to the second eye comprised the drug cost only.  
The class of IOP-lowering therapy prescribed to an individual was documented at the 
time of review, but no prescription information (e.g. product, dose, quantity or date 
prescribed) was recorded. The maximum dose of each IOP medication for each 
recorded class was taken from the British National Formulary and the volume of eye 
drops required per 28 days, which covers the shelf life of IOP-lowering drops, was 
calculated based on previously published data12–14 or an estimate of 20 drops per ml. 
The need for bilateral treatment with the same drug classes was taken into account 
in the calculation. A cost per day was generated for each IOP-lowering product listed 
in the Prescription Cost Analysis (PCA) for England 2015.15 A weighted average cost 
per class per day was then generated based on the number of items of each product 
dispensed in the PCA 2015. Where an eye was treated with more than one IOP-
lowering class at any one time, it was assumed that combination products would 
have been prescribed where available. 
 
Statistical analysis 
Costs were compared before and after index date using the Wilcoxon signed ranks 
test because healthcare resource use and costs were not normally distributed. 
Statistical analyses were carried out using IBM SPSS Statistics version 20. The costs 
are detailed as their mean value and standard deviation (SD), as per convention.  
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Results 
Patient characteristics at FAc implant 
208 people were eligible for inclusion in the study, contributing 233 FAc treated 
eyes. 208 (89%) eyes were first eyes treated with FAc implant. Mean (SD) age at 
implant was 68.1 (10.7) years and 62% of people were male. 15% of people had type 
1 diabetes and 85% of people had type 2 diabetes (Table 1). 
205 (88%) treated eyes had a pseudophakic lens prior to FAc implant (Table 1). 
Median (interquartile range, IQR) visual acuity was 0.66 (0.48–1.00) LogMAR units at 
the time of implant. Mean (SD) central foveal thickness was 428 (186) µm. 146 
(63%), 191 (82%) and 101 (43%) of subjects had previously been treated with 
macular laser therapy, anti-VEGF therapy or steroids other than FAc prior to the 
insertion of the FAc implant. 
 
Healthcare resource use and costs in the 12 months prior to and post FAc 
implant 
Healthcare resource use and costs in the 12 months prior to and post FAc intravitreal 
implant are detailed in Table 3. FAc treated eyes were prescribed significantly 
(p<0.001) more anti-VEGF therapies in the 12 months prior to FAc implant compared 
with the 12-month period post implant (mean [SD] 2.8 [2.5] versus 0.6 [1.4] 
injections). The number of steroid injections per eye was also higher in the 12 
months prior to implant (mean [SD] 0.14 [0.4] versus 0.08 [0.4], p=0.016). However, 
there was no statistically significant difference in the number of laser therapies 
required per eye in the 12 months prior to and post FAc implant (mean 0.12 versus 
0.11, respectively, p=0.626). When compared with the 12 month period post FAc 
implant, the number of vitrectomies (mean 0.06 versus 0.02, p=0.022), cataract 
operations (mean 0.24 versus 0.07, p<0.001) and outpatient appointments (mean 
6.7 versus 6.2, p<0.033) were all higher in the 12 month period prior to implant. 
There was no statistically significant difference in the number of OCT sans carried 
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out in the 12 months before and after FAc implant (mean 3.6 [SD 2.7] versus 3.5 
[2.2], p=0.987). 
When the drug and administration costs associated with prescribing the FAc implant 
were included in the cost estimate, the overall healthcare cost was higher in the 12 
months following FAc implant (mean £6,919 versus £2,691, p<0.001; Table 3). 
However, excluding the drug and administration costs associated with prescribing 
the FAc implant, overall healthcare costs were higher in the 12 months period prior 
to FAc implant (£1,239 versus £2,691, p<0.001). 
The mean number of concomitant treatments for DMO prescribed per eye was 
higher for each of the four quarters prior to implant when compared with the four 
quarters after implant (Figure 1a). The mean number of cataract surgeries carried 
out per eye was highest in each quarter prior to FAc implant and in the first quarter 
post implant (Figure 1b). However, it is important to note that 15 out of 17 surgeries 
recorded in the first quarter post FAc implant were carried out on the same day as 
the implant was inserted. The mean number of vitrectomies carried out per eye for 
each quarter remained low for the 12 months prior to and post FAc implant and only 
two glaucoma surgeries were recorded in the 12 months following implant. As 
anticipated, the mean number of outpatient attendances per eye was highest in the 
first quarter post FAc implant (including the outpatient appointment attended to 
administer the implant, Figure 1c). The lowest mean number of outpatient 
attendances was observed in quarters 2, 3 and 4 post implant. Excluding the drug 
and administration costs associated with prescribing the FAc implant, observed 
healthcare costs were lower in each of the four quarters post implant when 
compared with the same period prior to implant (Figure 1d). This was largely due to 
a decrease in the mean number of additional anti-VEGF and steroid therapies 
prescribed, which resulted in a corresponding decrease in DMO treatment and 
administration costs. The mean drug and administration cost associated with 
prescribing the FAc implant was £5,680. 
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Discussion 
A statistically significant reduction in anti-VEGF therapies, steroid therapies, 
outpatient appointments and vitrectomies were observed in the 12 months 
following FAc implant when compared with the 12 months prior to implant. 
Excluding the cost of the actual FAc intravitreal implant and the cost associated with 
its insertion, healthcare resource costs were halved (from £2,691 to £1,239) in the 
12 months following the FAc implant compared with the 12 months before implant. 
However, when the cost of FAc implant was included, post-implant cost was higher 
than the cost prior to implant. The drug and administration cost associated with 
inserting the FAc implant was £5,680, but, due to its prolonged duration of action, no 
drug and administration costs for the FAc implant should be incurred in the 
subsequent three years, only those costs associated with monitoring and managing 
adverse events. Using data from the ICE-UK study, we have previously reported that 
45%, 32% and 21% of FAc treated eyes improved by ≥5, ≥10 and ≥15 ETDRS letters at 
12 months post FAc implant, respectively, despite a mean decrease in visual acuity 
and central foveal thickness in the year prior to FAc implant.16,17 In addition to the 
visual benefits observed over the first 12 months following implant,16 sustained 
improvements in visual acuity were observed for up to three years post implant.6  
 When the cost of the FAc intravitreal implant was excluded, the reduction in cost 
observed post implant was largely due to a reduction in the frequency of anti-VEGF 
therapy and its administration. No significant change in the number of laser 
treatments administered prior to and post implant was observed and three of the 
study sites did not allow for anti-VEGF use after FAc implantation. The Diabetic 
Retinopathy Clinical Research Network reported a steady decrease in the number of 
ranibizumab injections administered over the trial’s five year follow-up period, with 
no corresponding decrease in visual acuity.18,19 In the FAME study, the use of laser 
and anti-VEGF treatments was more common in the sham (untreated) arm of the 
study compared with FAc 0.2 µg/day.6 Conversely, as FAc 190 µg intravitreal implant 
is only licensed in eyes that have been insufficiently responsive to other therapies, 
the reduction in the use of anti-VEGF therapies in the 12 months post implant may 
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reflect prior non-response to these agents. Previous insufficient responsiveness to 
available DMO therapies was not a requirement for selection into the FAME study, 
however a decrease anti-VEGF therapy was still observed.6 Intensive intravitreal 
injection regimens have been previously reported to have an effect on the quality of 
life of people with DMO.20 
Compared with anti-VEGF therapies, the FAc implant has the advantage of requiring 
substantially less frequent intravitreal injections, and therefore improved patient 
compliance, reduced treatment burden and reduced resource use have been 
previously cited as possible advantages.21 However, monitoring for complications is 
recommended two to seven days after insertion of the implant and then at least 
quarterly thereafter,22 necessitating regular visits to the ophthalmology outpatient 
department. However, in this study, a small but significant decrease in the number 
of outpatient appointments was observed, perhaps owing to the reduction in the 
number of anti-VEGF intravitreal injections administered. No significant difference in 
the number of OCT scans carried out was observed prior to and post implant. 
Side effects associated with steroids as a class include cataracts and raised IOP. 
However, the cost of IOP-lowering medication, monitoring and glaucoma surgery 
both before and after implant represented a very small segment of the overall cost 
of DMO care. More cataract operations were recorded prior to FAc implant and most 
treated eyes had a pseudophakic lens at the time of implant. This is most likely to be 
due to the NICE recommendation in the UK that the FAc intravitreal implant be used 
only in eyes with a pseudophakic lens.7 Yang and colleagues have shown that similar 
or possibly better outcomes can be achieved in those undergoing cataract surgery 
following FAc implantation compared with pseudophakic eyes treated with FAc 
implant.23 
Several studies have reported on the cost-effectiveness of treatments for DMO. 
Pershing and colleagues investigated the cost-effectiveness of laser monotherapy or 
anti-VEGF or triamcinolone alone or in combination with laser therapy in diabetic 
macular oedema and reported that costs were reduced with all interventions except 
laser monotherapy; the number of quality-adjusted life years (QALYs) increased for 
all interventions except for triamcinolone monotherapy.24 Bevacizumab is cheaper 
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than aflibercept or ranibizumab but remains unlicensed for DMO. However, 
bevacizumab has been demonstrated to be more cost-effective than aflibercept and 
ranibizumab in DMO.25 The FAc intravitreal implant was approved by NICE for the 
management of DMO in eyes with an artificial lens and licensed for the treatment of 
DMO that is insufficiently responsive to other available therapies.7 The NICE 
Appraisal Committee determined that, in eyes with a pseudophakic lens, the 
incremental cost-effectiveness ratio (ICER) of FAc was between £17,500 and £30,000 
per QALY gained, depending on the utilities used and providing that the FAc implant 
was supplied under the terms of the patient access scheme. NICE concluded that FAc 
intravitreal implant in pseudophakic eyes was therefore a cost-effective use of NHS 
resources. In an economic evaluation of the FAc implant by Moore and colleagues 
based on the results of the FAME studies, the expected incremental cost-
effectiveness ratio for treatment with an FAc implant was reported to be $38,763 
(approximately £30,800) when 40% of people are treated unilaterally, and cost-
saving (ICER -$10,620 per QALY) when 100% of people are treated unilaterally.8  
 
Strengths and limitations 
Advantages and disadvantages of the ICE-UK study have been discussed previously.16 
As this is an observational study, several limitations may occur. Misclassification of 
outcomes, effectiveness and safety may have occurred, although data were taken 
from patient notes and electronic medical records. Retrospective studies are subject 
to confounding and can only be used to infer association and not causation. Duration 
of DMO at the time of implant was not recorded. It was not possible to determine 
the individual’s exact age or their duration of diabetes at implant because these 
were recorded at their last clinic visit only, the date of which was not supplied. 
Discrepancies between lens status and cataract operations were observed and have 
been discussed previously.16 As it was important to determine the date of any 
intervention or procedure, recorded cataract operations were included in the study 
but lens changes were not. This may have led to an underestimation of the number 
and total cost of cataract operations. The recording of procedures occurring near to 
the end of the study observation period (15 April 2016) may not be complete as it 
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was possible for procedure dates to predate review dates. Analysis was restricted to 
12 months follow-up post implant because available follow-up after this date varied 
from person to person. No cost was applied to IOP-lowering medication when the 
class prescribed was specified as ‘other’. 
First and second treated eyes from the same person were analysed as independent 
observations. However, second eyes may be more likely to be treated with FAc 
implant if the subject had a positive response to treatment in the first eye. In 
addition, treatment of the second eye may be more likely to occur at certain 
treatment centres.  
Certain assumptions were made in costing ranibizumab, which is available as both a 
prefilled syringe and a vial.14 The prefilled syringe is designed to be used for the 
treatment of a single eye. The vial is available as a vial plus injection kit, a vial only 
pack and a vial plus filter needle pack. It was assumed that, for bilateral treatment 
with the same drug on the same date, different product packs would be used to 
treat each eye when the same drug was administered bilaterally on the same date.  
Another limitation is that ranibizumab, aflibercept and FAc intravitreal preparations 
indicated for DMO are listed on the NICE Patient Access Scheme list26 and supplied 
to the NHS at a discounted rate. In this study, however, the list price of the drug was 
used, as any price agreements between the manufacturer and the Department of 
Health under the Patient Access Scheme are not publically available. 
 
Conclusion 
The ICE-UK study was designed to investigate the real-world effectiveness of FAc 190 
µg intravitreal implant. Various standard clinical outcomes of care for DMO when 
treated with the FAc implant are reported in this supplement.16 Most of the study 
eyes included in the study had been treated with anti-VEGFs prior to FAc 
implantation, and mean visual acuity in the 12 months prior to FAc implant declined. 
Following intravitreal implantation, vision improved on average to a modest extent. 
Whilst it improved in some people, it at least stabilised with no further deterioration 
in the majority of the remaining subjects. During the 12 month follow-up period, 
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30% of patients were prescribed concomitant treatments for DMO. In this study we 
report that, following exclusion of the cost of the FAc implant itself, there was a 
corresponding decrease in healthcare resource usage over this period compared 
with the 12 months prior to implant. The cost of treating raised intraocular pressure 
was relatively low. Bearing in mind that this disease process typically involves 
increasing visual morbidity over time, and that the FAc implant functions for at least 
three years, it is likely that there will be an overall cost saving over this extended 
period, as has been reported in a previous economic evaluation.16 Furthermore, 
patient benefits include a lesser need for more frequent anti-VEGF treatments, 
although the FAc implant is recommended for use in eyes that have already shown 
an insufficient response to these therapies. Following a single administration, the 
FAc implant improves or maintains visual acuity and thus the quality of life of the 
recipient over an extended period of time. Therefore, the FAc implant provides the 
next logical step in the treatment algorithm of resistant DMO.  
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Tables and figures 
Table 1 | Unit cost of healthcare resources utilised  
Resource Cost Details 
Bevacizumab (unlicensed indication) £48 Cost of Avastin 5mg/0.2ml manufactured as an unlicensed special formulation. Personal 
communication via email from Shakeel Herwitker (Shakeel.Herwitker@rlbuht.nhs.uk), Royal 
Liverpool and Broadgreen University Hospital, 17 January 2016. 
Aflibercept £816 dm+d list price for Eylea®10 
Ranibizumab £551 dm+d list price for Lucentis®10 
Dexamethasone £870 dm+d list price for Ozudex®10 
Triamcinolone (unlicensed indication) £1.49 dm+d list price for Kenalog®10 
Fluocinolone acetonide £5,500 dm+d list price for Iluvien®10 
Outpatient appointment £59 NHS National Tariff 2014-159 WF01A follow-up outpatient attendance follow-up single 
professional, treatment function 130. 
Outpatient procedure for drug 
administration 
£137 National Tariff 2014-159, HRG BZ23Z Vitreous retinal procedure category 1  
Outpatient laser photocoagulation £137 National Tariff 2014-159, HRG BZ23Z Vitreous retinal procedure category 1 
Outpatient OCT £137 National Tariff 2014-159, HRG BZ23Z Vitreous retinal procedure category 1 
Glaucoma surgery £720 NHS National Tariff 2014-159 combined day case/ordinary elective spell tariff. Weighted 
mean calculated based on number of admissions for each HRG in HES 2014/15. Weighted 
mean = 26%*1,213 (BZ17Z) + 31%*783 (BZ18Z) + 44%*367 (BZ19Z). 
Vitrectomy £1,097 National Tariff 2014-159, HRG BZ22Z Vitreous retinal procedure category 2 
Cataract operation £699 HRG BZ02Z Phacoemulsification cataract extraction and lens implant combined day 
case/ordinary elective spell tariff. More than one relevant HRG was available. However, as 
HRG BZ02Z is applied to approximately 95% of cataract operations according to HES 2014-15 
data, this was deemed to be the most appropriate HRG for this study. 
dm+d = Dictionary of medicines and devices, NHS = National Health Service, HRG = Healthcare Resource Group, OCT = optical coherence tomography, HES = Hospital 
Episode Statistics. 
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Table 2 | Characteristics at FAc implant 
Parameter Value 
Subjects, n 208 
 
First eyes treated, n (%)a 208 (89%) 
Second eyes treated, n (%)b 25 (11%) 
All treated eyes, n (%) 233 
 
   
Patient characteristics 
  
Age last clinic visit, mean (SD)c 68.1 (10.7) 
Males, n (%) 128 (62%) 
Type 2 diabetes, n (%) 176 (85%) 
Oral antihyperglycaemic agents 76 (43%) 
Insulin 43 (24%) 
Insulin plus oral antihyperglycaemic agents 57 (32%) 
Type 1 diabetes, n (%) 32 (15%) 
Oral antihyperglycaemic agents 0 (0%) 
Insulin 28 (88%) 
Insulin plus oral antihyperglycaemic agents 4 (13%) 
Number of years with diabetes, median (IQR)c 18 (11-27)    
Eye characteristics 
  
Pseudokaphic lens status, n (%)d 205 (88%) 
Visual acuity, LogMAR units 
  
n (%) 224 (96%) 
Median (IQR) 0.66 (0.48-1) 
Visual acuity, ETDRS letters   
n (%) 224 (96%) 
Median (IQR) 52 (35–61) 
Centre subfield thickness, m 
  
n (%) 198 (85%) 
Median (IQR) 447 (352-587) 
Central foveal thickness, m 
  
n (%) 191 (82%) 
mean (SD) 482 (186) 
IOP, mmHg 
  
n (%) 185 (79%) 
Median (IQR), mmHg 15 (13-18) 
Prior macular laser treatments 
  
n (%) 146 (63%) 
Median (IQR) 1 (0-1) 
Prior anti–VEGF injections 
  
n (%) 191 (82%) 
Median (IQR) 3 (1-6) 
Prior ranibuzimab injections 
  
n (%) 162 (70%) 
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Median (IQR) 3 (0-5) 
Prior aflibercept injections 
  
n (%) 1 (0%) 
Median (IQR) 0 (0-0) 
Prior bevacizumab injections 
  
n (%) 74 (32%) 
Median (IQR) 0 (0-1) 
Prior steroid injections, 
  
n (%) 101 (43%) 
Median (IQR) 0 (0-1) 
Prior dexamethasone injections 
  
n (%) 17 (7%) 
Median (IQR) 0 (0-0) 
Prior triamcinolone injections 
  
n (%) 88 (38%) 
Median (IQR) 0 (0-1) 
IOP-lowering medication, n (%) 42 (18%) 
Prostaglandin analogues, n(%) 26 (11%) 
Beta blockers, n (%) 17 (7%) 
Alpha agonists, n (%) 5 (2%) 
Carbonic anhydrase inhibitors, n (%) 5 (2%) 
Other, n (%) 8 (3%) 
SD = standard deviation, IQR = interquartile range,  LogMAR = logarithm of the minimum angle of 
resolution, VEGF = vascular endothelial growth factor, IOP = intraocular pressure.
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Table 3 | Healthcare resource use and costs before and after FAc implant 
 
Prior to implant Post implant* p-value  
N Mean (SD) N Mean (SD) 
Healthcare resource use 
       
Ranibizumab 607 2.6 (2.5) 122 0.5 (1.4) <0.001 
Bevacizumab 37 0.2 (0.7) 2 0.0 (0.1) <0.001 
Aflibercept 5 0.0 (0.3) 17 0.1 (0.6) 0.244 
Dexamethasone 6 0.0 (0.2) 4 0.0 (0.2) 0.317 
Triamcinolone 27 0.1 (0.3) 15 0.1 (0.3) 0.028 
Laser photocoagulation 28 0.1 (0.4) 25 0.1 (0.4) 0.626 
FAc implant 0 0.0 (0) 233 1.0 (0) <0.001 
OCT 828 3.6 (2.7) 812 3.5 (2.2) 0.987 
Glaucoma surgery 0 0.0 (0) 2 0.0 (0.1) 0.157 
Vitrectomy 15 0.1 (0.3) 4 0.0 (0.1) 0.022 
Cataract surgery 56 0.2 (0.4) 17 0.1 (0.3) <0.001 
Outpatient appointments 1556 6.7 (3.1) 1454 6.2 (2.8) 0.033         
Healthcare costs, £ 
       
Overall 627,058 2,691 (1,850) 1,612,184 6,919 (1,195) <0.001 
Overall excluding FAc implant 627,058 2,691 (1,850) 288,702 1,239 (1,203) <0.001 
SD = standard deviation, FAc = fluocinolone acetonide, OCT = ocular coherence tomography. 
* Healthcare resources used on the day of FAc implant and their corresponding costs are included in the post implant healthcare resource use and cost estimates. 
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Figure 1 | Quarterly updated healthcare resource use and costs in the 12 
months prior to and post FAc implant 
a) Mean number of treatments per eye for diabetic macular oedema  
 
b) Mean number of daycase and inpatient admissions per eye 
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c) Mean number of outpatient attendances per eye (including outpatient 
attendances for FAc implant) 
 
d) Mean healthcare cost per eye, per quarter 
 
VEGF = vascular endothelial growth factor, OCT = ocular coherence tomography, IOP = intraocular 
pressure. 
Healthcare resources used on the day of FAc implant and their corresponding costs are included in 
the post implant healthcare resource use and cost estimates.  
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